



September 18th



Frederic B. Ayers Senior Consultant – Microbiology ValSource, Inc. fayers@valsource.com



September 18th



Agenda

- PDA Technical Report No. 90
- Build It
- Foundation
- **Contamination Controls**
- Validation Controls

Monitoring Controls Governance Feedback Loops ATMP Specifics



September 18th

Contamination Control Strategy – PDA Technical Report No. 90







- Holistic vs. Non-holistic examples (throughout)
- List of process & technical information needed to inform CCS (section 3.0)
- Current expectations for in-process monitoring limits of biologics (section 4.0)
- Table of Container Closure Integrity considerations (section 10.0)
- Roadmap to relevant Industry Guidance Docs (section 14.0)



September 18th

Contamination Control Strategy – Build It



- Build an interdisciplinary Team Identify a CCS Lead
- Must be truly cross-functional
- Multiple levels of the organization
- CCS Lead coordinates efforts
- CCS Lead ensures input from functional area experts
- Create Knowledge Management around CCS Process
- Culture Change that focuses on preventing contamination



Manager,

control

allocations

and inventory





- Execute a gap assessment to regulatory requirements
- Create a formal CAPA plan to mitigate documented gaps
- Ensure the *BLINDERS* are off
- Identify current assessments
- Identify needed assessments and fill the QRM gaps
- Write CCS doc(s)...
- More gaps may be identified (additional CAPA to close)
- Establish periodic review of CCS
- Require CCS impact assessment as part of QMS





e^{293:}**202**⁴ Offor Eventrals of Contamination Control Strategies

September 18th

Contamination Control Strategy – Foundation







September 18th



Scientific Knowledge

Process / Technical Knowledge

Quality Risk Management

Personal Awareness & Quality Culture





September 18th

The control strategy is the protective layer your organization builds to protect product quality and a patient safety.

> Risk Assessment and Scientific Rationale are the foundation of your control strategy .

> > The foundation of your strategy needs continuous care to ensure relevance.



September 18th

The House of CCS



Governance

the Foundations



September 18th

Contamination Control Strategy – Contamination Controls











September 18th

Facility & Utilities Material & Waste Personnel Flow Personnel Hygiene & Gowning

Raw Materials



The House of CCS

September 18th



Governance

defined oversight and escalation



Change Control



September 18th

Contamination Control Strategy – Validation Controls













- Several training modalities:
 - Reading
 - Computer Based
 - Instructor led
 - On the job









Change Control



September 18th

Contamination Control Strategy – Monitoring Controls



September 18th



Monitoring Controls

Validation Controls

Contamination Controls

Foundation



September 18th



4.1 The manufacture of sterile products should be carried out in appropriate cleanrooms, entry to which should be through change rooms that act as airlocks for personnel and airlocks for equipment and materials. Cleanrooms and change rooms should be maintained to an appropriate cleanliness standard and supplied with air that has passed through filters of an appropriate efficiency. Controls and monitoring should be scientifically justified and should effectively evaluate the state of environmental conditions of cleanrooms, airlocks and pass-through hatches.

5.2 Equipment monitoring requirements should be defined in "user requirements specifications" during early stages of development, and confirmed during qualification. Process and equipment alarm events should be acknowledged and evaluated for trends. The frequency at which alarms are assessed should be based on their criticality (with critical alarms reviewed immediately).

5.6 All equipment such as sterilisers, air handling systems (including air filtration) and water systems should be subject to qualification, monitoring and planned maintenance. Upon completion of maintenance, their return to use should be approved.













September 18th

Contamination Control Strategy – Governance







September 18th



Escalation

Oversight





- CCS Lead SME Team Members:
 - Quality Risk Management Manufacturing Operations / Process Experts Contamination Control / Sterility Assurance Engineering / Facilities / Utilities Equipment Validation Raw Materials / Vendor Oversight Quality Control
 - Quality Assurance

- Program Owner / Steward:
 - Empowered System Owner
 - Collaboration with various functional groups
 - Linkage to other aspects of the Quality Management System
 - Movement through all the elements of the CCS
 - Always asks the question "is there impact to the CCS?"





September 18th

Contamination Control Strategy – Feedback Loops



Key Process Indicators

- Reactive
- Proactive
- Capital Investment / Re-Investment
- Quality Risk Management activities
- CAPA Effectiveness
- **Conformance to CCS Program**
 - Qualification / Validation / Verification
 - **Risk Assessment**
 - Maintenance







September

18th









September 18th

Contamination Control Strategy – ATMP Specifics



September 18th



Facilities & Utilities

Special design considerations for multi-product and multi-patient operations with multiple suites and/or multiple workstations for segregation purposes

> Many of the recently designed facilities have VHP capabilities for manufacturing areas and transfer of materials / components entering the cleanrooms, which requires full isolation of these areas (especially for those processes using multiple viral vectors for gene modification)

Equipment

Newer process equipment are designed to be automated (or semiauto), "closed" systems for aseptic unit operations (cell growth / harvesting / activation / etc...)

> A risk-based approach is thus key in evaluating the entirety of the system, the processing steps, and the environment in order to determine appropriate levels of controls and monitoring.



September 18th



Personnel

Highly manual and aseptic thus aseptic practices are incredibly important so there should be a focus on training, qualification, and quality / design of procedures.

> Operator fatigue is common and can be overlooked for personnel working within the cleanrooms increasing contamination related risks.

Materials

Ancillary materials of biological origin (human- and animalderived) are used in cell therapy processes thus controls for reducing introduction of adventitious viruses and other contaminants are essential, as well as traceability of materials to

origin

Manufacturers need to work with the suppliers to ensure the overall CCS is robust.



September 18th



Vendors / Suppliers Many materials and components are unique and custom, there may be only a single supplier (or very limited number) offering 'research-grade' only quality and these materials may not be manufactured to GMPs.

> Supplier selection, auditing, and additional testing / controls are important to assess (e.g., sterilization filtration of solutions prior to use in the cell therapy process by a process that is validated may be needed).

Containers / Closures Many cell therapy products and intermediates need to be stored at cryo-temperatures where the materials of construction for bags / containers (typically constructed with FEP) and their components are fragile.

> Materials need to be handled and stored, appropriately, based upon the hazards associated with the shipping / transport of these finished products.



September 18th



Process Validation Cell therapy products cannot be terminally sterilized, most of the production steps are aseptic.

Design of APS can be complex and difficult to manage, as well as difficult to determine root cause if a contamination / failure is observed



September 18th



Governance

defined oversight and escalation



Investigation/CAPA



